Efficacy and cost effectiveness of moxifloxacin versus cefotaxime +/- macrolides for the treatment of patients with community-acquired pneumonia in Russia

Trial Profile

Efficacy and cost effectiveness of moxifloxacin versus cefotaxime +/- macrolides for the treatment of patients with community-acquired pneumonia in Russia

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2012

At a glance

  • Drugs Amoxicillin/clavulanic acid; Amoxicillin/clavulanic acid; Azithromycin; Cefotaxime; Ceftriaxone; Clarithromycin; Moxifloxacin; Moxifloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2012 Additional treatment groups/descriptors added, patient numbers updated to 167, and treatment details updated/added
    • 06 Jun 2012 Updated results presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 28 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top